HedgeChatter

  • Home /
  • Tag Archives

SGYPW

Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation

[at noodls] – Topline Data Show That Plecanatide Met Primary and Key Secondary Endpoints NEW YORK, Jan. 2, 2013 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that plecanatide, its investigational oral … moreView todays social media effects on SGYPWView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to view […]

January 3, 2013 Bystocknews , Comments Off on Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation read more

Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C)

[at noodls] – NEW YORK, Dec. 27, 2012 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that dosing has commenced in a Phase … moreView todays social media effects on SGYPWView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to […]

December 27, 2012 Bystocknews , Comments Off on Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C) read more

Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis

[at noodls] – Scientific Poster Presentation at 2012 Advances in IBD Conference NEW YORK, Dec. 14, 2012 — Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and … moreView todays social media effects on SGYPWView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to view […]

December 14, 2012 Bystocknews , Comments Off on Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis read more

Synergy Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

[at noodls] – NEW YORK, Nov. 21, 2012 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its President and CEO, Gary S. Jacob, … moreView todays social media effects on SGYPWView the latest stocks trending across Twitter. Click to view dashboard […]

November 21, 2012 Bystocknews , Comments Off on Synergy Pharmaceuticals to Present at Piper Jaffray Healthcare Conference read more

Synergy Pharmaceuticals Reports Third Quarter 2012 Financial Results

[at noodls] – Synergy Advances Clinical Programs NEW YORK, Nov. 13, 2012 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its … moreView todays social media effects on SGYPWView the latest stocks trending across Twitter. Click to view dashboard […]

November 13, 2012 Bystocknews , Comments Off on Synergy Pharmaceuticals Reports Third Quarter 2012 Financial Results read more

Synergy Pharmaceuticals Announces Extension for Filing of Third Quarter Form 10-Q Due to Hurricane Sandy

[at noodls] – NEW YORK, Nov. 9, 2012 — Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that, in accordance with applicable rules … moreView todays social media effects on SGYPWView the latest stocks trending across Twitter. Click to view dashboard […]

November 9, 2012 Bystocknews , Comments Off on Synergy Pharmaceuticals Announces Extension for Filing of Third Quarter Form 10-Q Due to Hurricane Sandy read more